<DOC>
	<DOCNO>NCT02337933</DOCNO>
	<brief_summary>The metabolic syndrome characterize presence overweight/obesity , insulin resistance , hyperglycemia , dyslipidaemia hypertension inflammatory state , together increase risk develop cardiovascular disease ( CVD ) diabetes mellitus type 2 ( DM2 ) . It also characterize decreased insulin sensitivity , namely , low ability insulin metabolize glucose , key physiopathogeny disease process . In search pharmacological agent attend component metabolic syndrome improve insulin sensitivity effectively prevent development CVD DM2 , ursolic acid promise compound . Ursolic acid pentacyclic carboxylic acid present medicinal herb , part fruit like apple peel , plant rosemary . There scientific evidence important benefit ursolic acid level vitro vivo insulin , metabolism lipid glucose , well body weight metabolic parameter . However , result clear mechanism fully elucidados . The aim study evaluate effect ursolic acid insulin sensitivity metabolic syndrome .</brief_summary>
	<brief_title>Effect Ursolic Acid Administration Insulin Sensitivity Metabolic Syndrome</brief_title>
	<detailed_description>A randomized , double-blind , placebo-controlled clinical trial 24 patient sex age 30 60 year , diagnosis metabolic syndrome accord modify IDF criterion , without treatment . They assign randomly two group 12 patient , receive 150 mg ursolic acid placebo breakfast 12 week . Insulin sensitivity calculate Matsuda Index date glucose insulin level Oral Glucose Tolerance Test ; Waist circumference measure ; tryglicerides High density lipoprotein ( HDL-C ) blood pressure evaluate intervention group . Statistical analysis present measure central tendency dispersion , average deviation standard quantitative variable ; frequency percentages variable qualitative . Qualitative variable analyze X2 , use difference inter-group Mann-Whitney U Test Wilcoxon Test within-groups difference . Will consider statistical significance p ≤0.05 . This protocol approve local ethic committee ( CEI/075/2014 ) write informed consent obtain volunteer .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<mesh_term>Hypersensitivity</mesh_term>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Ursolic acid</mesh_term>
	<mesh_term>Magnesium Oxide</mesh_term>
	<criteria>Informed consent sign Patients sexes Age 30 60 year Metabolic Syndrome accord IDF criterion : Waist circumference Man ≥90 cm , Woman ≥80 cm ; two follow criterion : High density lipoprotein Man ≤40 mg/dL , Woman ≤50 mg/dL ; Fasting glucose ≥100 mg/dL ; Triglycerides ≥150 mg/dL ; Blood pressure ≥130/85 mmHg Women confirm suspected pregnancy Women lactation and/or puerperium Hypersensibility ursolic acid calcine magnesia Physical impossibility take pill Known uncontrolled renal , hepatic , heart thyroid diseased Previous treatment metabolic syndrome component Body Mass Index ≥39.9 kg/m2 Fasting glucose ≥126 mg/dL Triglycerides ≥500 mg/dL Total cholesterol ≥240 mg/dL Low density lipoprotein ( cLDL ) ≥190 mg/dL Blood Pressure ≥140/90 mmHg</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Metabolic Syndrome</keyword>
	<keyword>Central Obesity</keyword>
	<keyword>Insulin Sensitivity</keyword>
	<keyword>Ursolic Acid</keyword>
	<keyword>Triterpenoid</keyword>
</DOC>